Table 2.
Clinical demographics of Cohort 1 (34 patients).
| Background | Complete blood count# | ||
| Sex (M/F) | 25/9 | Red blood cell (× 104/µL) (n = 34) | 422.4 ± 12.13 |
| Age (years old) (median, range) | 37 (17–92) | Hemoglobin (g/dL) (n = 34) | 12.49 ± 0.3149 |
| Height (cm)*, # | 164.4 ± 1.6 | Hematocrit (%) (n = 34) | 37.69 ± 0.9129 |
| Body weight (kg)*,# | 54.4 ± 1.9 | MCV (fL) (n = 34) | 89.93 ± 1.191 |
| Body mass index*,# (mean, range) | 20.1 ± 0.6 | MCH (pg) (n = 34) | 29.84 ± 0.4896 |
| UC disease duration (years) (median, range) | 5.0 (0.1–31.0) | MCHC (g/dL) (n = 34) | 33.15 ± 0.1728 |
| UC disease type (total colitis/left-sided colitis) | 28/6 | White blood cell (× 103/µL) (n = 34) | 7.431 ± 0.4484 |
| Treatment history for UC | Neutrophil (%) (n = 32) | 67.63 ± 1.625 | |
| 5-ASA (+ /−) | 33/1 | Eosinophil (%) (n = 32) | 3.258 ± 0.6002 |
| Azathioprine (+ /−) | 13/21 | Basophil (%) (n = 32) | 0.5636 ± 0.07951 |
| Prednisolone (+ /−) | 29/5 | Monocyte (%) (n = 32) | 8.976 ± 0.5657 |
| Anti TNF-alpha agent (+ /−) | 12/22 | Lymphocyte (%) (n = 32) | 19.52 ± 1.392 |
| Tofacitinib (+ /−) | 1/33 | Platelet (× 104/µL) (n = 34) | 33.77 ± 1.652 |
| Tacrolimus (+ /−) | 3/31 | Blood chemistry# | |
| Granulocyte and monocyte apheresis (+ /−) | 3/31 | BUN (mg/dL) (n = 31) | 9.825 ± 0.8679 |
| Concomitant treatment for UC | Creatinine (mg/dL) (n = 32) | 0.7091 ± 0.02694 | |
| 5-ASA (+ /−) | 21/13 | eGFR (mL/min) (n = 32) | 98.73 ± 4.065 |
| Azathioprine (+ /−) | 8/26 | Total bilirubin (mg/dL) (n = 32) | 0.4188 ± 0.03491 |
| Prednisolone (+ /−) | 8/26 | AST (IU/L) (n = 34) | 18.44 ± 1.624 |
| Clinical activity of UC | ALT (IU/L) (n = 34) | 15.03 ± 2.051 | |
| Lichtiger index (median, range) | 9 (5–16) | GGT (IU/L) (n = 30) | 29.47 ± 5.878 |
| Partial Mayo score (median, range) | 6 (4–9) | Total protein (g/dL) (n = 34) | 6.540 ± 0.1535 |
| Endoscopic activity of UC (n = 31) | Albumin (g/dL) (n = 33) | 3.447 ± 0.1301 | |
| Mayo endoscopic subscore (median, range) | 2 (2–3) | Globulin (g/dL) (n = 33) | 3.094 ± 0.08412 |
| UCEIS | 6 (3–9) | Total cholesterol (mg/dL) (n = 27) | 147.3 ± 6.191 |
| UCEIS-V | 2 (1–3) | CRP (mg/dL) (n = 32) | 1.780 ± 0.4263 |
| UCEIS-E | 2 (1–3) | Achievement of SFCR at week 22 (yes/no) | 18/16 |
| UCEIS-B | 2 (0–3) | ||
*Height, body weight, and body mass index were not measured in one subject.
#Height, body weight, body mass index and the results of blood tests are described as the mean ± SEM.